Indonesia’s Bio Farma Awaiting Gov’t Nod for IndoVac Clinical Trials on Children
IndoVac is a homegrown Covid-19 vaccine produced by Bio Farma.
JAKARTA, KOMPAS.com – Indonesia’s state-owned pharmaceutical company PT Bio Farma is still waiting for the government approval before conducting clinical trials of IndoVac vaccine on children aged six to 11 in the country. IndoVac is a homegrown Covid-19 vaccine produced by Bio Farma. "If the government wants [to give the IndoVac vaccine] for children in the Covid-19 vaccination program, we can finish the clinical trials in three months," Bio Farma president director Honesti Basyir said on Tuesday, Dec.13. The government launched Covid-19 vaccination program for children on Dec. 14, 2021. Howe...